Genetic predictors of five-year outcomes of acute coronary syndrome

Aim. To determine the genetic predictors of five-year outcomes in patients with acute coronary syndrome (ACS).

Material and methods. The study included patients admitted to the City clinical hospital № 1 (CCH №1) in Novosibirsk with a diagnosis of ACS in the period 2010-3 2011 (n=280). All patients were examined in accordance with clinical guidelines and standards of care, genetic markers were assessed. Genotyping included determination of single nucleotide polymorphisms (SNPs), confirming its association with the development of the ACS according to the results of an international genomeassociated studies: rs1376251, rs4804611, rs 1333049, rs619203, rs10757278, rs2549513, rs499818, rs17465637. All patients are kept in touch from the moment of initial contact to the present time, with the help of available means of communication and annual examinations in order to assess the end points. “End points” included: repeated nonfatal myocardial infarction (MI), hospitalization for myocardial ischemia, re-revascularization or chronic heart failure (CHF), nonfatal acute cerebrovascular accident (NACA), cardiovascular death.

Results. We revealed SNPs, which play a role in predicting long-term outcomes of ACS: rs10757278, rs 4804611, rs 1333049, rs 2549513. The genotype of rs2549513 as 2,9-fold (95% CI 1,06-8,03; p=0,041) increases the risk of unfavorable long-term prognosis in the subgroup of men older than 55 years. The AA genotype rs10757278 and GG genotype rs1333049 are associated with a favorable long-term prognosis (OR=0,47, 95% CI 0,23-0,96; p=0,042 and OR=0,41, 95% CI 0,22-0,78; p=0,049, respectively) in the group of patients older than 55 years. For the GG genotype rs1333049 association was characteristic only for women. The AA genotype rs4804611 is associated with a favorable outcome of ACS at the age of 55 years (OR=0,036, 95% CI 0,14-0,96; p=0,053), significant differences were obtained in the group of men (p=0,36).

Conclusion. The use of identified genetic predictors to assess the risk of five-year outcomes will strengthen a personalized approach to patients and, together with conventional prevention measures, will reduce cardiovascular mortality.

1. Marco Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. Eur Heart J. 2016 Jan 14;37(3):267-315. doi:10.1093/eurheartj/ehv320. Epub 2015 Aug 29.

2. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;(6):7-122. (In Russ.) doi:10.15829/1560-4071-2018-6-7-122.

3. Boytsov SA, Provatorov SI. Cardiovascular diseases in the Russian Federation: the main components of mortality and prevention. Vestnik Roszdravnadzora. 2018;5:12-8. (In Russ.)

4. Boytsov SA, Samorodskaja IV, Nikulina NN, et al. Comparative analysis of mortality from acute forms of coronary heart disease for the fifteen-year period in the Russian Federation and the USA and the factors affecting its formation. Terapevticheskij arhiv. 2017;89(9):53-9. (In Russ.) doi :10.17116/terarkh201789953-59.

5. Mortality of the population of the Novosibirsk region from diseases of the circulatory system in 2017. Novosibirskstat. Press-reliz № 149 from 23 July 2018. (In Russ.) http://novosibstat.gks.ru/wps/wcm/connect/rosstat_ts/novosibstat/ru/publications/news_issu es/6e1c5680465f9e70ae08eeedfce35b80

6. Fox KA, Fitzgerald G, Puymirat E, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open. 2014;4(2):e004425.

7. Maksimov VN, Orlov PS, Ivanova АА, et al. Complex evaluation of the significance of populational genetic markers associated With myocardial infarction and risk factors. Russ J Cardiol. 2017;22(10):33-41. (In Russ.) doi:10.15829/15604071-2017-10-33-41.

8. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(38):119-77 doi:10.1093/eurheartj/ehx393.

9. Lozhkina NG, Maksimov VN, Orlov PS, et al. Genetic markers of negative outcomes of the acute coronary syndrome. Russ J Cardiol. 2014;19(10):19-22. (In Russ.) doi:10.15829/1560-4071-2014-10-19-22.

10. Lozhkina NG, Khasanova MH, Kuimov AD, et al. Multifactorial Prognostication of Remote Outcomes in Patients With Non-ST Elevation Acute Coronary Syndrome. Kardiologiia. 2017;57(8):28-33. (In Russ.) doi: 10.18087/cardio.2017.8.10014.

11. Lozhkina NG, Maksimov VN, Ragino YuI, et al. Multifactor prediction of long-term outcomes of acute coronary syndrome with sustained ST segment elevation. Russ J Cardiol. 2015;20(9):25-31. (In Russ.) doi:10.15829/1560-4071-2015-09-25-31.

12. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Russ J Cardiol. 2017;22(6):7-85. (In Russ.) doi:10.15829/1560-4071-2017-6-7-85.

13. Szpakowicz A, Kiliszek M, Pepinski W, et al. Polymorphism of 9p21.3 locus is associated with 5-year survival in high-risk patients with myocardial infarction. PLoS One. 2014; 9(8):e104635. doi:10.1371/journal.pone.0104635.